ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-β/Smad-induced growth arrest of prostate cells

Oncogene

Volumn 25, Issue 41, 2006, Pages 5591-5600

  Noda, D ^a,b   Itoh, S ^a,c   Watanabe, Y ^a   Inamitsu, M ^a   Dennler, S ^c   Itoh, F ^a,c   Koike, S ^b   Danielpour, D ^d   Ten Dijke, P ^c,e   Kato, M ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell proliferation; ELAC2; p21; Smad TGF

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; PROTEIN ELAC2; PROTEIN P21; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FAST 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE FUNCTION; GENETIC TRANSCRIPTION; GROWTH DISORDER; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN INTERACTION;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEIN BINDING; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748659836     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209571     Document Type: Article

References (45)

1. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S et al. (2004). Sicence 303: 848-851.
2. Chen G, Nomura M, Morinaga H, Matsubara E, Okabe T, Goto K et al. (2005a). J Biol Chem 280: 36355-36363.
3. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. (1997). Nature 389: 85-89.
4. Chen Y, Beck A, Davenport C, Chen Y, Shattuck D, Tavtigian SV. (2005b). BMC Mol Biol 6: 12.
5. Danielpour D. (2005). Eur J Cancer 41: 846-857.
6. Datto MB, Yu Y, Wang XF. (1995). J Biol Chem 270: 28623-28628.
7. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier J-M. (1998). EMBO J 17: 3091-3100.
8. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M et al. (1995). Cancer Res 55: 2910-2919.
9. Feng X-H, Lin X, Derynck R. (2000). EMBO J 19: 5178-5193.
10. Goldman LA, Cutrone EC, Kotenko SV, Krause CD, Langer JA. (1996). Biotechniques 21: 1013-1015.
11. Guo Y, Jacobs SC, Kyprianou N. (1997). Int J Cancer 71: 573-579.
12. Guo Y, Kyprianou N. (1998). Cell Growth Differ 9: 185-193.
13. Guo Y, Kyprianou N. (1999). Cancer Res 59: 1366-1371.
14. Heldin C-H, Miyazono K, ten Dijke P. (1997). Nature 390: 465-471.
15. Itoh S, Ericsson J, Nishikawa J, Heldin C-H, ten Dijke P. (2000). Nucleic Acids Res 28: 4291-4298.
16. Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin C-H et al. (2003). J Biol Chem 278: 3751-3761.
17. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. (1998). EMBO J 17: 4056-4065.
18. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M et al. (1996). Clin Cancer Res 2: 1255-1261.
19. Korver W, Guevara C, Chen Y, Neuteboom S, Bookstein R, Tavtigian S et al. (2003). Int J Cancer 104: 283-288.
20. Kundu SD, Kim IY, Yang T, Doglio L, Lang S, Zhang X et al. (2000). Prostate 43: 118-124.
21. Larisch-Bloch S, Danielpour D, Roche NS, Lotan R, Hsing AY, Kerner H et al. (2000). Cell Growth Differ 11: 1-10.
22. Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF. (1995). J Biol Chem 270: 26750-26753.
23. Massagué J, Blain SW, Lo RS. (2000). Cell 51: 295-309.
24. Minagawa A, Takaku H, Takagi M, Nashimoto M. (2005). Cancer Lett 222: 211-215.
25. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. (2002). Genes Cells 7: 1191-1204.
26. Moustakas A, Kardassis D. (1998). Proc Natl Acad Sci USA 95: 6733-6738.
27. Moustakas A, Souchelnytskyi S, Heldin C-H. (2001). J Cell Sci 114: 4359-4369.
28. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E et al. (1998). EMBO J 16: 5353-5362.
29. Nakashima K, Yanagisawa M, Arakawa H, Ochiai W, Arakawa H, Taga T. (1999). Science 284: 479-482.
30. Nicolas FJ, De Bosscher K, Schmierer B, Hill CS. (2004). J Cell Sci 117: 4113-4125.
31. Persson U, Izumi H, Souchelnytskyi S, Itoh S, Grimsby S, Engström U et al. (1998). FEBS Lett 434: 83-87.
32. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A. (2000). J Biol Chem 275: 29244-29256.
33. Roberts AB, Sporn MB. (1990) In: Sporn MB and Roberts AB (eds). Peptide Growth Factors and Their Receptors Part I, vol. 95. Springer-Verlag: Berlin, pp 419-472.
34. Seoane J, Le HV, Shen L, Anderson SA, Massagué J. (2004). Cell 117: 211-223.
35. Shea PR, Ferrell RE, Patrick AL, Kuller LH, Bunker CH. (2002). Hum Genet 111: 398-400.
36. Shi Y, Massagué J. (2003). Cell 113: 685-700.
37. Siegel PM, Massagué J. (2003). Nat Rev Cancer 3: 807-821.
38. Song K, Cornelius SC, Danielpour D. (2000). Cancer Res 63: 4358-4367.
39. Takaku H, Minagawa A, Takagi M, Nashimoto M. (2003). Nucleic Acids Res 31: 2272-2278.
40. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP et al. (1999). Cancer Res 59: 4834-4842.
41. Tavtigian SV, Simard J, Teng DHF, Abtin V, Baumgard M, Beck A et al. (2001). Nat Genet 27: 172-180.
42. ten Dijke P, Goumans M-J, Itoh F, Itoh S. (2002). J Cell Physiol 191: 1-16.
43. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. (1994). Nature 370: 341-347.
44. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF et al. (2001). Cancer Res 61: 6494-6499.
45. Zhou S, Zawel L, Lengauer C, Kinzler KW, Vogelstein B. (1998). Mol Cell 2: 121-127.